Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Adebrelimab (SHR-1316)NSCLCChemotherapy
Interventions
DRUG

Adebrelimab

Adebrelimab 1200mg,ivgtt,D1,Q3W

DRUG

chemotherapy

"Queue A (lung squamous cell carcinoma patients):~Albumin paclitaxel 260mg/m2, ivgtt,D1 , Q3W Carboplatin AUC=5, D1,Q3W~Queue B (lung adenocarcinoma patients):~Pemetrexed 500 mg/m2, ivgtt,D1,Q3W Carboplatin AUC=5, D1,Q3W"

All Listed Sponsors
lead

Zhangzhou Municipal Hospital

OTHER